Form 10-Q · Quarterly report
Honeywell Technologies 10-Q, filed Jul 23, 2026
- Filed
- CIK
- 0000773840
- Accession no.
- 0000773840-26-000124
Summary
Honeywell International's second-quarter 2026 net sales rose 4% year over year, as 4% pricing, a 1% foreign-currency benefit, and 1% acquisitions offset a 1% volume decline and a 2% divestiture impact, while gross margin percentage fell 170 basis points to 37.6%. The quarter included a $6.629 billion gain on the deconsolidation of Quantinuum, a $311 million year-to-date impairment on assets held for sale tied to Productivity Solutions and Services and Warehouse and Workflow Solutions, and a 12% increase in backlog to $38.0 billion ahead of the Aerospace Spin-Off.
Key points
- Q2 2026 net sales rose 4% from a year earlier, with price +4%, foreign currency +1%, acquisitions +1%, volume -1%, and divestitures -2%.
- Gross margin percentage decreased 170 basis points to 37.6% in Q2 2026, and total research and development costs rose to $828 million from $719 million.
- Honeywell recorded a $6.629 billion gain on deconsolidation of Quantinuum and a $265 million equity loss on Quantinuum following the deconsolidation.
- Backlog increased 12% to $38.0 billion as of June 30, 2026, including $18.435 billion in Aerospace Technologies.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
ITEM 2. MANAGEMENT’S DISCUSSION RESULTS OF OPERATIONS 37 Honeywell International Inc. TABLE OF CONTENTS Consolidated Financial Results Net Sales by Segment 38 Honeywell International Inc. TABLE OF CONTENTS 39 Honeywell International Inc. TABLE OF CONTENTS Segment Profit by Segment 40 Honeywell International Inc. TABLE OF CONTENTS CONSOLIDATED OPERATING RESULTS Net Sales The change in Net sales was attributable to the following: Q2 2026 vs. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.